AR-12
No one needs that much cancer-fighting capability!
Posted on 07/17/2016 10:06:40 AM PDT by MarchonDC09122009
http://www.express.co.uk/news/science/688379/Breakthrough-cancer-super-drug-can-also-be-used-to-beat-ebola-and-HIV
By Sean Martin 16:59, Mon, Jul 11, 2016 | UPDATED: 17:06, Mon, Jul 11, 2016
Breakthrough cancer super-drug can also be used to beat ebola and HIV
The breakthrough cancer therapy could be a “universal” therapy against flu and has the ability to destroy bacteria which has been failed by traditional medicines.
Scientists behind the discovery say that the drug works by hurting the engine of viruses and cancers in cells while not affecting the rest of the body.
The drug, known as AR-12, is now being brought to the UK by a pharmaceutical company for clinical trials against HIV.
AR-12 also has the backing of the US army who plan to incorporate it in a project that will see the drug used as a last resort against against viruses such as ebola.
AR-12
No one needs that much cancer-fighting capability!
“AR-12”..... we simply just can’t have that.
If I recall correctly, the Israelis initially discovered and pursued this. Hope it lives up to expectations.
And this is the last we will ever hear of it.
You beat me, sucker!.... :0)
Are you saying the R & D was not done by those Research Hospitals that Yassar Arrafat built with the Billions the U.N. gave him? Oh wait a minute....where did the money go?
OSU-03012 - Wikipedia, the free encyclopedia
https://en.wikipedia.org/wiki/OSU-03012 Proxy Highlight
OSU-03012 (AR-12) is a celecoxib derivative with anticancer and anti-microbial activity. Unlike celecoxib, OSU-03012 does not inhibit COX, but inhibits several other important enzymes instead which may be useful in the treatment of some forms of cancer, while also having antifungal activity via disruption of ... The European Commission has designated AR-12 as an orphan drug for ...
AR-12 - Arno Therapeutics, Inc.
www.arnothera.com/ar12.html Proxy Highlight
AR-12. Drug Description AR-12 is a potentially first-in-class, orally available, targeted anti-cancer agent that has been shown in preclinical studies to inhibit ...
Arno Therapeutics to Inhibit Cancer and Enhance Portfolios: CEO Alexander Zukiwski [ARNI]
TLSR: What can you tell me about Arno’s third compound, AR-12?
AZ: There is evidence that AR-12 hits the glucose-regulated protein 78 (GRP 78) chaperone. This is a master regulator of unfolded protein response. For normal cells, it doesn’t cause any major toxicity, but it has tremendous potential activity against various diseases. In addition, AR-12 inhibits heat shock protein (Hsp) 70 and Hsp 90 chaperones. Our colleagues at OSU demonstrated that AR-12 also induces and enhances autophagy in host effector cells.
“We are optimistic that AR-42 could have activity in different solid tumors.”
Through a series of collaborations, AR-12 was shown to have in vitro activity against various microbial pathogens. What is exciting is that this novel mechanism of action potentially allows for development of a host-targeted antimicrobial agent. By targeting host cells instead of microbes, AR-12 may not be subject to typical drug resistance mechanisms reported for certain antiviral agents and antibiotics. We are currently developing a series of collaborations to further explore the potential of AR-12 in the antimicrobial space.
TLSR: What disease targets are of interest for your first studies?
AZ: AR-12 has published activity against certain fungal species. Furthermore, our colleagues from Virginia Commonwealth University have recently published data demonstrating AR-12 to have activity against a series of viruses and antibiotic-resistant bacteria. Before selecting disease targets, we want to understand the spectrum of activity. Next, we intend to focus development on those areas deemed to have the highest likelihood of success, and where there is a clear medical need.
TLSR: What are the catalysts or milestones that investors should look for with respect to each of your compounds?
AZ: First will be completion of the onapristone Phase 2 study in recurrent and metastatic endometrioid cancer. For AR-42, we are looking for an increasing amount of data from the Phase 2 studies in various tumor types. For AR-12, being at an opportunistic phase, we are determining the best avenue for development in the infectious disease space. All of these are possible over the next two years.
Consider the ramifications of this:
Find a cure for HIV?
The floodgates of unrestrained fudge packers and carpet munchers will be opened wide, and sodomy will be celebrated as just another “healthy life style” choice.
Find a cure for Ebola?
All residents of Ebola-prone African nations will be given a warm, unconditional welcome to visit and STAY in the United States.
Be careful what you wish for.
I hope the drug is indeed as good as initial indications show.
Thanks for posting this.
Virginia Commonwealth University
Go Rams!
5.56mm
Careful. This article could be part of a carefully orchestrated pump-and-dump scheme for the stock, which is traded on the OTCBB.
The medicine may well live up to its high expectations. As someone who works in the health care sector, I simply hope that each new clinical trial inches us closer to a good understanding of how to halt and/or prevent diseases.
Company A’s stock price is low. The execs buy up as many shares as possible. Company A announces a new wonder drug that can cure cancer and Ebola and hepatitis and a host of other maladies. Company A’s stock goes through the roof. The execs sell their stocks. Later the research data on the drug is revealed as bogus (just like 50% of all current drug research. The execs and their pals at the FDA retire and move to Cancun.
Rinse and repeat.
HIV. The gift from excrement-eating homosexuals to an unsuspecting populace.
‘Gay Pride’?
I’m so confused ;-)
how about:
(s)a computer with more than an 8088 processor is a hate crime!(/s)
I am sure there will be a few more tweaks and iterations to the drug before its totally finalized.
Imagine if libtards are saved by an ar-15.
Cures cancer, will be FDA approved in 50 years.
It’s an assault drug.
Sadly, my first thought when I read the article was, with the current administration, the greatest obstacle in this sort of discovery is to decide how much the kickback will be and who is going to get it.
(Okay, I'm an old Chicago boy. Show me anything in the past with this bunch makes me wrong on this deal...)
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.